Abbott Laboratories (ABT) Total Non-Current Liabilities (2009 - 2021)

Abbott Laboratories has reported Total Non-Current Liabilities for 13 years, with the latest figure at $17.5 billion in Q4 2021.

• Quarterly Total Non-Current Liabilities rose 1.26% year-over-year to $17.5 billion in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $17.5 billion (up 1.26% YoY) and the FY2021 annual result came in at $17.5 billion, up 1.26% from the prior year.
• Total Non-Current Liabilities climbed to $17.5 billion in Q4 2021 per ABT's latest filing, from $17.3 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $71.4 billion in Q4 2017 and troughed at $14.1 billion in Q4 2019.
• A 5-year average of $36.7 billion and a median of $17.5 billion in 2021 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2017 and 2019: Total Non-Current Liabilities soared 48.38% in 2017, then sank 77.74% in 2019.
• Over 5 years, Total Non-Current Liabilities stood at $71.4 billion in 2017, then fell by 11.49% to $63.2 billion in 2018, then tumbled by 77.74% to $14.1 billion in 2019, then grew by 22.81% to $17.3 billion in 2020, then gained by 1.26% to $17.5 billion in 2021.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $17.5 billion, $17.3 billion, and $14.1 billion for Q4 2021, Q4 2020, and Q4 2019 respectively.